ArticleNature communications2026
Asymmetric synthesis of Heteroatom-bridged [3.2.1]Octane scaffolds via enantioselective β-H elimination reaction.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
N-bridged [3.2.1]octanes (tropanes) and their related bridged bicyclic systems constitute highly sought-after scaffolds in drug discovery and development. Notably, the enantioselective synthesis of chiral 3-aryltropanes which are compounds widely distributed across bioactive pharmaceutical agents remains underdeveloped. Tropinone is a readily available and cost-effective starting material. By initiating the synthesis from tropinone, it is possible to substantially lower the synthesis costs. Here we describe an enantioselective Pd/Ming-Phos-catalyzed β-H elimination reaction of Tropinone-derived N-arylsulfonylhydrazones and aryl bromides to give chiral tropanes and oxatropanes. Strikingly, this study achieves enantioselective β-H elimination which needs to simultaneously control over both diastereoselectivity during the migratory insertion and enantioselectivity during the β-H elimination. This approach shows broad functional group tolerance, good enantiocontrol as well as easy scale-up. Moreover, the synthetic value is further demonstrated by the enantioselective catalytic total synthesis of drugs for treating Alzheimer's disease and monoamine transporter ligands. Additionally, both the facile elaborations and the preliminary biological activities of the products demonstrate the application potential.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.